Improving vaccine design, particularly through the careful selection of antigens and adjuvants, while focusing on the role of CD4+ T cells in tumor-targeted vaccines, alongside the incorporation of combination immunotherapy, will be crucial strategies for enhancing the efficacy of vaccines aimed at treating GBM. The gene discussed is CD4; the disease is glioblastoma.